Revenue: As of FY2026 Q1, the actual value is USD 19.47 M.

EPS: As of FY2026 Q1, the actual value is USD -1.39.

EBIT: As of FY2026 Q1, the actual value is USD -79.74 M.

Revenue

GINKGO BIOWORKS HOLDINGS, INC. reported first quarter 2026 revenue of $19 million, a 49% decrease from $38 million in the comparable prior year period . Excluding $7 million of non-cash revenue from a deferred revenue release in Q1 2025, revenue decreased by 37% from $31 million in the comparable prior year period to $19 million in Q1 2026, primarily due to ongoing program rationalization as part of restructuring activities .

GAAP Net Loss from Continuing Operations

The GAAP net loss from continuing operations for the first quarter of 2026 was -$76 million, an improvement from -$83 million in the comparable prior year period .

Adjusted EBITDA

Adjusted EBITDA for the first quarter of 2026 was -$42 million, compared to -$44 million in the comparable prior year period .

Operational Expenses (Continuing Operations)

• Cost of other revenue: $3,098 thousand in Q1 2026, down from $4,090 thousand in Q1 2025 .
• Research and development: $49,920 thousand in Q1 2026, down from $70,923 thousand in Q1 2025 .
• General and administrative: $37,830 thousand in Q1 2026, down from $39,723 thousand in Q1 2025 .
• Restructuring charges: $0 thousand in Q1 2026, down from $4,466 thousand in Q1 2025 .
• Total operating expenses: $90,848 thousand in Q1 2026, down from $119,202 thousand in Q1 2025 .

Loss from Operations (Continuing Operations)

Loss from operations was -$71,374 thousand in Q1 2026, improving from -$80,972 thousand in Q1 2025 .

Cash Flow and Balances

• Cash, Cash Equivalents and Marketable Securities: The balance as of March 31, 2026, was $373 million .
• Net Cash Used in Operating Activities: Total net cash used in operating activities was -$46,686 thousand in Q1 2026, an improvement from -$51,521 thousand in Q1 2025 .
  • Net cash used in operating activities from continuing operations: -$46,433 thousand in Q1 2026, compared to -$42,749 thousand in Q1 2025 .
  • Net cash used in operating activities from discontinued operations: -$253 thousand in Q1 2026, compared to -$8,772 thousand in Q1 2025 .

Unique Operational Metrics

GINKGO BIOWORKS HOLDINGS, INC. is targeting to double the size of its Nebula autonomous lab in 2026 . The Cloud Lab, Datapoints, and Solutions offerings are generating revenue and accelerating the development of the autonomous lab .

Full Year 2026 Outlook

GINKGO BIOWORKS HOLDINGS, INC. reaffirms its expected total cash burn for the full year 2026 to be between -$150 million and -$125 million .